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1  |  INTRODUC TION
In 2016, the 69th World Health Assembly endorsed the Global 
Health Sector Strategy for Viral Hepatitis, embracing a goal to elim-
inate hepatitis infection as a public health threat by 2030.1 This was 
followed by the World Health Organization's (WHO) global targets 
for the care and management of hepatitis B virus (HBV) and hepatitis 
C virus (HCV) infections.2 These announcements and targets were 
important in raising awareness and calling for action. Since then, 
tracking countries’ progress towards these elimination goals has 
provided insights to the limitations of these targets.3 We recognize 
that the global COVID-19 pandemic has impacted priorities, but we 
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Abstract
The 69th World Health Assembly endorsed the Global Health Sector Strategy for 
Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health 
threat by 2030. This was followed by the World Health Organization's (WHO) global 
targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus 
(HCV) infections. These announcements and targets were important in raising aware-
ness and calling for action; however, tracking countries’ progress towards these elimi-
nation goals has provided insights to the limitations of these targets. The existing 
targets compare a country's progress relative to its 2015 values, penalizing countries 
who started their programmes prior to 2015, countries with a young population, or 
countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis 
elimination targets, (2) change to absolute targets and (3) allow countries to achieve 
these disease targets with their own service coverage initiatives that will have the 
maximum impact. The recommended targets are as follows: reduce HCV new chronic 
cases to ≤5 per 100 000, reduce HBV prevalence among 1-year-olds to ≤0.1%, re-
duce HBV and HCV mortality to ≤5 per 100 000, and demonstrate HBV and HCV 
year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our 
recommendations is not to lower expectations or diminish the hepatitis elimination 
standards, but to provide clearer targets that recognize the past and current elimina-
tion efforts by countries, help measure progress towards true elimination, and moti-
vate other countries to follow suit.
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recommend that these targets be updated to better reflect the orig-
inal goals—clear, measurable targets that better signpost progress 
towards true viral hepatitis elimination.
2  |  PROBLEMS
First, the current impact targets for reduction in mortality and inci-
dence are relative to a 2015 baseline (Table 1) when hepatitis epidemi-
ology data were not being systematically collected in most countries. 
The 2015 relative targets also penalize countries that had a low 
starting point in 2015. Countries with young HCV-infected popula-
tions (eg, Australia and United Kingdom [UK]) will have a difficult time 
achieving the current mortality targets, even with robust national 
elimination programmes, since their 2015 mortality was already low. 
Similarly, countries with a low incidence in 2015 (eg, the Netherlands 
for HCV; much of Western Europe and the Americas for HBV) will 
have difficulty reaching an additional 90% incidence reduction by 
2030. Second, the current guidelines are ambiguous. A 90% reduction 
in incidence of chronic HBV infections (compared to 2015 baseline) 
is inconsistent with a 0.1% prevalence of HBV infection in children 
five years of age in 2030 as suggested by WHO.4 The former favours 
TA B L E  3  Countries/regions reaching the existing WHO elimination targets by 2030
Note: Blue countries/regions—those not achieving the absolute targets for a similar category in Table 4; only countries/ regions analysed by Polaris 
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countries that began universal vaccination between 2015-2020 (eg, 
Japan and UK), while the latter favours countries/regions that have 
had long-standing vaccination programmes prior to 2015 (eg, China & 
Taiwan). Finally, the service coverage targets are confusing since they 
do not include all options available to countries (eg, antiviral treat-
ment of pregnant women, use of hepatitis B immune globulin).
TA B L E  4  Countries/regions reaching the absolute HBV and HCV elimination targets by 2030
Note: Blue countries/regions—those not achieving the current targets for a similar category in Table 3, only countries/regions analysed by Polaris 
Observatory are listed; CAR: Central African Republic, DPR Korea: Democratic People's Republic of Korea, UAE: United Arab Emirates, UK: United 
Kingdom.




≤5 per 100,000 







HCV reduce new 
chronic infections to 
≤5 per 100,000
HCV reduce 
mortality to ≤5 per 
100,000 & decrease 
in new HCC cases
Countries/ regions 
meeting all HCV 
targets
Albania Kosovo Finland Finland Argentina Australia Australia
Algeria Kuwait Japan Japan Australia Austria Austria
Argentina Kyrgyzstan Austria Brazil Brazil
Armenia Latvia Belgium Cameroon Canada
Australia Lebanon Brazil Canada Egypt
Austria Libya Canada CAR France
Azerbaijan Lithuania Chile Chad Germany
Bangladesh Macedonia Costa Rica Egypt Iceland
Belarus Malaysia Croatia France Italy
Belgium Mexico Denmark Georgia Japan
Brazil Moldova Dominican Republic Germany Korea, Republic of
Bulgaria Mongolia Egypt Iceland Netherlands
Cambodia Morocco El Salvador Italy Spain
Canada Nepal France Japan Turkey
Chile Netherlands Germany Korea, Republic of UK
China New Zealand Iceland Latvia
Colombia Nicaragua Israel Libya
Costa Rica Norway Italy Lithuania
Croatia Oman Japan Madagascar
Cuba Panama Korea, Republic of Netherlands
Czechia Peru Lebanon New Zealand
DPR Korea Poland Mexico Rwanda
Denmark Portugal Netherlands Spain
Dominican Republic Qatar Portugal Sweden
Ecuador Romania Saudi Arabia Switzerland
Egypt Russia Slovenia Turkey
El Salvador Saudi Arabia Spain UK
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3  |  RECOMMENDATION
We recommend that (1) WHO simplify the hepatitis elimination tar-
gets, (2) change to absolute targets shown in Table 2 and (3) allow 
countries to achieve these disease targets with their own service 
coverage initiatives that will have the maximum impact. The recom-
mended targets roughly correspond to the WHO targets but are 
translated to absolute numbers. Table 2 also shows different levels 
of recommended measures to track progress towards these goals. 
The reduction in mortality must be coupled with a decrease in new 
HBV/HCV-related hepatocellular carcinoma (HCC) cases: a measur-
able surrogate for overall liver-related mortality. Countries with a 
low viral hepatitis prevalence may meet the mortality target and still 
have an increasing incident number of HBV/HCV-related HCC cases. 
This combination will ensure that steps are taken to reduce HBV/
HCV mortality and disease burden.
Using models developed by Polaris Observatory, the projected 
countries that will achieve the existing 2030 WHO elimination tar-
gets and the recommended absolute targets are shown in Table 3. 
The analyses are based on historical treatment and screening data 
up to 2019 with projections to 2030, not including the impact of the 
COVID-19 pandemic. There has been a negative impact on hepati-
tis-related services; however, the full impact of COVID-19 is difficult 
to incorporate at the time of this analysis.
Using existing criteria, only three countries are expected to 
achieve the 90% reduction in HBV incidence. None will achieve a 
65% reduction in mortality relative to 2015, and no country will 
achieve all of the current HBV elimination targets. Similarly, only 
four countries are expected to achieve all of the current HCV elim-
ination targets.
Hepatitis B virus surface antigen (HBsAg) prevalence among 
5-year-olds reflects the impact of prophylaxis programmes insti-
tuted 5 years earlier. Table 4 shows that changing the target for 
prevalence among children from 5-year-olds to 1-year-olds would 
allow another 20 countries to achieve the absolute target of ≤0.1% 
by 2030. This reflects the benefits of their vaccination programmes 
over the additional 4 years. This measure also correlates well with a 
low incidence (≤5 per 100 000) among the total population. Thus, a 
separate (relative) target is not needed.
An estimated 76 countries will meet an HBV mortality rate of 5 
per 100 000, but only two will also have a year-on-year reduction of 
HCC cases (Finland and Japan). This highlights the need for further 
debate, beyond the scope of this editorial, regarding the current in-
ternational and national HBV treatment guidelines that are too nar-
row and restrictive to sufficiently result in a year-to-year decrease in 
HBV-related HCC cases.
Table 4 also shows that moving from a relative reduction in HCV 
incidence to an absolute cut-off of ≤5 per 100 000 allows 25 addi-
tional countries with low HCV prevalence to meet the new targets. 
It makes little sense to expect a country with a low HCV prevalence 
and incidence to spend resources to further reduce incidence if HCV 
is not considered a large public health problem. Similarly, moving to 
an absolute target of ≤5 per 100 000 for HCV mortality allows all 
countries that started with a low mortality rate in 2015 to achieve 
the new targets (15 countries). Overall, an additional 11 countries 
are expected to achieve all new targets relative to the existing WHO 
elimination targets.
The objective of our recommendations is not to lower expecta-
tions or diminish the hepatitis elimination standards, but to provide 
clearer targets that recognize the past and current elimination ef-
forts by countries, help measure progress towards true elimination, 
and motivate other countries to follow suit. We also believe that 
countries are in the best position to select the mix of service cover-
ages that will allow them to meet these revised global targets. This 
is particularly important during the COVID-19 pandemic that may 
have led to diversion of resources from the hepatitis programmes. 
After 5 years of progress and assessment, we strongly recommend 
that WHO reconsiders and refines the existing elimination targets 
in 2020.
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